RBT is launching the production of a set for creating personalized vaccines for the treatment of cancer in small pets. RBT vaccines activate the pet's immune system to fight the tumor. Currently, there are only two solutions in the line: a set for creating a personalized multi-antigen vaccine against lymphomas in cats and dogs, and a set with the Betusfera a...

Artgen will buy back RBT shares from investors who invested at least ₽1 million during the 2023 Rounds platform placement and retained ownership of the shares since their purchase. Buyback will be conducted at the investment price. Holders of the shares can exercise their right between April 20 and May 20, 2026.

Shareholders of RBT company decided to increase the authorized capital by additional issue of shares to attract investments in the updated strategy. Company plans to place an additional issue in a closed subscription format at ₽130 per share and raise about ₽60 million in the first half of 2026.

VISUS LAB has developed Blepharosept eyelid hygiene gel and is preparing to start deliveries cosmetic products to retail chains. Product contains an innovative form of betulin developed by RBT - Betusphere. Addition of betulin to the gel provides a prolonged anti-inflammatory and wound healing effect aimed at relieving the symptoms of blepharitis and reducin...